


# CORTECS COLUMNS

APPLICATIONS NOTEBOOK



Waters

THE SCIENCE OF WHAT'S POSSIBLE.®

C<sub>18</sub><sup>+</sup>CORTECS UPLC 1.6  $\mu$ m Applications

	Literature Code	Page
Actinomycins from <i>Streptomyces</i> sp.	WA64678	4
Basic Impurities	WA64680	5
Beta Blockers	WA64672	6
Cat's Claw Bark ( <i>Uncaria Tomentosa</i> )	WA64679	7
Chlortalidone Base Degradation	WA64673	8
Intact Human Insulin and Five Analogs in Human Plasma	WA64695	9
Local Anesthetics	WA64675	10
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	WA64669	11
Omeprazole Tablet Acid Degradation	WA64676	12
Sulfa Drugs	WA64670	13
Tioconazole Impurities	WA64674	14
Tricyclic Antidepressants	WA64671	15

CORTECS 2.7  $\mu$ m Applications

Basic Impurities	WA64694	16
Reversed-Phase Quality Control Reference Material (QCRM)	WA60706	17

C<sub>18</sub>CORTECS UPLC 1.6  $\mu$ m Applications

Amoxicillin and Clavulanic Acid Oral Suspension	WA64690	18
Analgesics	WA64682	19
Antibacterials	WA64685	20
<i>Astragalus</i> Root	WA64692	21
Bradykinin in Human Plasma	WA64709	22
Caffeine Metabolites	WA64681	23
Catechins and Green Tea	WA64684	24
Cephalosporins	WA64688	25
<i>Cnidium Monnieri</i>	WA64691	26
Cold Medicine Compounds	WA64686	27
Erythromycins from <i>Streptomyces</i> sp.	WA64693	28

## C<sub>18</sub>

CONTINUED

### CORTECS UPLC 1.6 $\mu$ m Applications *Continued*

	Literature Code	Page
Estradiols and Tablet Sample	WA64687	29
Phenolics in Echinacea	WA64689	30
Statins	WA64683	31
Synthetic Cannabinoids from Urine	WA64699	32
Synthetic Cannabinoids from Whole Blood	WA64700	33

### CORTECS 2.7 $\mu$ m Applications

Abacavir Related Compounds	WA64697	34
Antibacterials	WA64696	35
LCMS Quality Control Reference Material (QCRM)	WA64705	36
Sudan Dyes	WA60708	37
Synthetic Cannabinoids	WA64698	38

## HILIC

### CORTECS UPLC 1.6 $\mu$ m Applications


Acetylcholine, Histamine, and their Metabolites in Human CSF	WA64702	39
Acyclovir and Guanine	WA64666	40
Cold Medicine Compounds	WA64667	41
Histidine Dipeptides	WA64668	42
Local Anesthetics	WA64664	43
Morphine Metabolites	WA64662	44
Nucleic Acid Bases	WA64663	45
Paraquat and Diquat in Drinking Water	WA64703	46
Paraquat and Diquat in Potato and Wheat	WA64710	47
Water Soluble Vitamins	WA64665	48

### CORTECS 2.7 $\mu$ m Applications


Basic Drugs in River Water	WA60707	49
HILIC Quality Control Reference Material (QCRM)	WA64704	50
Morphine Metabolites	WA64701	51

## CONDITIONS

System:	ACQUITY UPLC® with Xevo® G2 QToF Mass Spectrometer
Column:	CORTECS® UPLC® C <sub>18</sub> +, 1.6 µm, 2.1 x 50 mm (p/n 186007114)
Mobile phase A:	Water with 0.1% formic acid
Mobile phase B:	Acetonitrile with 0.1% formic acid
Flow rate:	0.6 mL/min
Gradient:	2 to 98% B in 5.5 minutes, hold 1 minute, equilibrate at 2% B
Run time:	7 minutes
Injection volume:	1 µL
Column temp.:	30 °C
Scan mode:	ESI+ 200–1500 amu
Cone voltage:	30 V
Desolvation gas:	800 L/hr
Desolvation temp.:	280 °C
Capillary voltage:	3 kV
Sample:	10 mL <i>Streptomyces</i> sp. fermentation broth extracted with 10 mL 80:20 EtoAc/methanol
Identification:	Compounds identified by accurate mass using MassLynx® Software




**Actinomycin D**  
mw: 1255.42  
C<sub>62</sub>H<sub>86</sub>N<sub>12</sub>O<sub>16</sub>



### CONDITIONS

System: ACQUITY UPLC® I-Class with ACQUITY® PDA  
 Columns: CORTECS® UPLC® C<sub>18</sub>+, 1.6 μm, 2.1 x 50 mm (p/n 186007114)  
 Competitor Solid-Core C<sub>18</sub>, 1.7 μm, 2.1 x 50 mm  
 Mobile phase A: 0.1% formic acid in water  
 Mobile phase B: 0.1% formic acid in acetonitrile  
 Detection: UV at 254 nm  
 Flow rate: 0.6 mL/min  
 Gradient: See table  
 Injection volume: 5.0 μL  
 Column temp.: 30 °C


Sample preparation: Imipramine (0.5 mg/mL), with various concentrations of amitriptyline (0.5, 2.5, 5, and 10%) prepared in water



Imipramine

Time (min)	Flow Rate (mL/min)	%A	%B
0.0	0.6	75	25
2.0	0.6	65	35
3.0	0.6	5	95
3.1	0.6	75	25
5.0	0.6	75	25


### Spiked impurity analysis




Comparative separations may not be representative in all applications.

### CONDITIONS


System:	ACQUITY UPLC® I-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> +, 1.6 μm, 2.1 x 50 mm (p/n 186007114)
Mobile phase A:	0.1% formic acid in water
Mobile phase B:	0.1% formic acid in acetonitrile
2D UV channels:	260 nm
Flow rate:	0.4 mL/min
Gradient:	See table
Sampling rate:	80 pts/sec
Time constant filter:	Fast
Injection volume:	1.0 μL
Column temp.:	30 °C
Sample diluent:	Water




Pindolol




Labetolol



Acebutolol




Propranolol




Oxprenolol

Time (min)	Flow Rate (mL/min)	%A	%B
0.0	0.5	95	5
4.5	0.5	5	95
5.0	0.5	5	95
5.1	0.5	95	5
6.0	0.5	95	5




### CONDITIONS


System:	ACQUITY UPLC® with Xevo® G2 QToF Mass Spectrometer
Column:	CORTECS® UPLC® C <sub>18</sub> +, 1.6 μm, 2.1 x 100 mm (p/n 186007116)
Mobile phase A:	Water with 0.1% formic acid
Mobile phase B:	Acetonitrile with 0.1% formic acid
Flow rate:	0.6 mL/min
Gradient:	15 to 30% B in 4.5 minutes, ramp to 90% B in 1 minute, hold to 7 minutes, equilibrate at 15% B
Run time:	8 minutes
Injection volume:	1 μL
Column temp.:	30 °C
Scan mode:	ESI+ 200–1000 amu
Cone voltage:	30 V
Desolvation gas:	800 L/hr
Desolvation temp.:	280 °C
Capillary voltage:	3 kV
Sample:	485 mg Cat's Claw Bark ( <i>Uncaria tomentosa</i> ) extracted with 4 mL 50:50 EtoAc/methanol
Identification:	Mass extracted from total ion chromatogram (TIC) and compounds identified by accurate mass using MassLynx® Software



**Rhynchophylline**  
C<sub>22</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub>  
mw 384.47




**Rhynchophylline-N-oxide**  
C<sub>22</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>  
mw 400.47




## CONDITIONS

System:	ACQUITY UPLC® I-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> +, 1.6 µm, 2.1 x 50 mm (p/n 186007114)
Mobile phase A:	0.1% formic acid in water
Mobile phase B:	0.1% formic acid in acetonitrile
Detection:	UV at 254 nm
Gradient:	See table
Injection volume:	1.0 µL
Column temp.:	30 °C
Sample diluent:	Methanol
Sample preparation:	Chlortalidone subjected to 0.2 mL 1 N sodium hydroxide and heated at 60 °C for 20 hours




**Chlortalidone**



**Chlortalidone Degradation Product:**  
2-Chloro-5-(1-methoxy-3-oxo-1-isoindolin-2-yl)-  
benzene sulfonamide

Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.6	95	5
5.0	0.6	5	95
5.5	0.6	5	95
5.6	0.6	95	5
7.0	0.6	95	5





**CONDITIONS**

System: ACQUITY UPLC® I-Class with 2D Technology, configured for at-column dilution with trap and back elution with Xevo® TQ-S Mass Spectrometer

Analytical column: CORTECS® UPLC® C<sub>18</sub>+, 1.6 μm, 2.1 x 50 mm (p/n 186007114)

Trap column: XBridge® C<sub>18</sub> IS™, 3.5 μm, 2.1 x 20 mm (p/n 186003019)

Elution mobile phase A: 0.1% formic acid in water

Elution mobile phase B: 0.1% formic acid in acetonitrile

Gradient: Load for two minutes; switch valve and back elute from trap column onto analytical column with a linear gradient from 15 to 40% B over four minutes

Elution flow rate: 0.25 mL/min



Column temp.: 60 °C

Sample temp.: 15 °C

Injection volume: 30 μL


Collection plates: Waters® 1-mL ACQUITY® collection plates

To see the full application note, visit [www.waters.com](http://www.waters.com) and search for literature code: 720004727EN




**CONDITIONS**


System: ACQUITY UPLC® I-Class with ACQUITY® PDA  
 Column: CORTECS® UPLC® C<sub>18</sub>+, 1.6 μm, 2.1 x 50 mm (p/n 186007114)  
 Mobile phase A: 0.1% formic acid in water  
 Mobile phase B: 0.1% formic acid in acetonitrile  
 Detection: UV at 245 nm  
 Gradient: See table  
 Flow rate: 0.6 mL/min  
 Injection volume: 1.0 μL  
 Column temp.: 30 °C  
 Sample diluent: Water




**Lidocaine**




**Bupivacaine**




**Butacaine**



**Tetracaine**




**Dibucaine**




**Benzocaine**

Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.6	95	5
1.0	0.6	65	35
2.0	0.6	65	35
5.5	0.6	5	95
5.6	0.6	95	5
7.0	0.6	95	5




### CONDITIONS


System: ACQUITY UPLC® I-Class with ACQUITY® PDA  
 Column: CORTECS® UPLC® C<sub>18</sub>+, 1.6 μm, 2.1 x 50 mm (p/n 186007114)  
 Mobile phase A: 0.1% formic acid in water  
 Mobile phase B: 0.1% formic acid in acetonitrile  
 Detection: UV at 270 nm  
 Data rate: 20 pts/sec  
 Filter time: Normal  
 Gradient: See table  
 Injection volume: 1.0 μL  
 Column temp.: 30 °C  
 Sample: NSAIDs mix at 50–100 μg/mL in water




Tolmetin




Fenoprofen



Naproxen




Indomethacin





Diclofenac

Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.8	65	35
2.2	0.8	35	65
2.3	0.8	35	65
2.4	0.8	65	35
3.0	0.8	65	35




## CONDITIONS

System:	ACQUITY UPLC® I-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> +, 1.6 μm, 2.1 x 50 mm (p/n 186007114)
Mobile phase A:	0.1% formic acid in water
Mobile phase B:	0.1% formic acid in acetonitrile
Detection:	UV at 254 nm
Gradient:	See table
Flow rate:	0.6 mL/min
Injection volume:	1.0 μL
Column temp.:	30 °C
Sample diluent:	50% methanol in water
Sample preparation:	Omeprazole subjected to 1 N HCl and left at room temperature for 20 minutes




Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.6	95	5
5.0	0.6	5	95
5.5	0.6	5	95
5.6	0.6	95	5
7.0	0.6	95	5




### CONDITIONS


System:	ACQUITY UPLC® H-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> +, 1.6 μm, 2.1 x 50 mm (p/n 186007114)
Mobile phase A:	0.1% formic acid in water
Mobile phase B:	0.1% formic acid in acetonitrile
Detection:	UV at 254 nm
Flow rate:	0.5 mL/min
Gradient:	See table
Injection volume:	4.0 μL
Column temp.:	30 °C
Sample diluent:	Water




Sulfathiazole




Sulfamerazine




Sulfamethazine




Sulfamethoxypyridazine



Sulfachloropyridazine




Sulfamethoxazole




Sulfasoxazole

Time (min)	Flow Rate (mL/min)	%A	%B
0.0	0.5	95	5
5.0	0.5	40	60
5.5	0.5	40	60
5.6	0.5	95	5
7.0	0.5	95	5




### CONDITIONS


System:	ACQUITY UPLC® with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> +, 1.6 μm, 2.1 x 50 mm (p/n 186007114)
Mobile phase A:	0.1% formic acid in water
Mobile phase B:	0.1% formic acid in acetonitrile
Detection:	UV at 219 nm
Gradient:	See table
Flow rate:	0.6 mL/min
Injection volume:	4.0 μL
Column temp.:	30 °C
Sample diluent:	Methanol
Sample:	Tioconazole USP Related Compounds




Tioconazole



Related Compound A




Related Compound B




Related Compound C

Time (min)	Flow Rate (mL/min)	%A	%B
0.0	0.6	98	2
4.0	0.6	25	75
4.5	0.6	25	75
4.6	0.6	98	2
6.0	0.6	98	2




### CONDITIONS


System: ACQUITY UPLC® H-Class with ACQUITY® PDA  
 Column: CORTECS® UPLC® C<sub>18</sub>+, 1.6 μm, 2.1 x 50 mm (p/n 186007114)  
 Mobile phase A: 0.1% formic acid in water  
 Mobile phase B: 0.1% formic acid in acetonitrile  
 Detection: UV at 254 nm  
 Flow rate: 0.6 mL/min  
 Gradient: See table  
 Injection volume: 1.0 μL  
 Column temp.: 40 °C  
 Sample diluent: Water




Nordoxepin




Nortriptyline



Trimipramine




Protriptyline




Amitriptyline

Time (min)	Flow Rate (mL/min)	%A	%B
0.0	0.6	72	28
3.0	0.6	65	35
3.5	0.6	5	95
3.6	0.6	72	28
6.0	0.6	72	28




### CONDITIONS

System:	Alliance® HPLC with 2998 Photodiode Array Detector
Column:	CORTECS® C <sub>18</sub> +, 2.7 μm, 4.6 x 150 mm (p/n 186007408)
Mobile phase A:	0.1% formic acid in water
Mobile phase B:	0.1% formic acid in acetonitrile
Detection:	UV at 254 nm
Flow rate:	1.5 mL/min
Gradient:	See table
Injection volume:	36 μL
Column temp.:	30 °C
Sample preparation:	Imipramine (0.5 mg/mL), with various concentrations of amitriptyline (10 μg/mL, 5 μg/mL, and 0.5 μg/mL) prepared in water



Imipramine


Time (min)	%A	%B	Curve
0.0	75	25	–
11.3	65	35	6
12.0	65	35	6
12.1	75	25	6
15.0	75	25	6






### CONDITIONS

System: ACQUITY UPLC® with PDA Detector  
 Column: CORTECS® C<sub>18</sub>+, 2.7 μm, 2.1 x 100 mm (p/n 186007397)  
 Mobile phase A: 0.1% formic acid in water  
 Mobile phase B: 0.1% formic acid in acetonitrile  
 Flow rate: 1.0 mL/min  
 Gradient: See table  
 Injection volume: 2.0 μL  
 Column temp.: 30 °C  
 Sample: Reversed-Phase QCRM (p/n 186006363)




Uracil




Propranolol



Acenaphthene




Butylparaben



Amitriptyline




Naphthalene




Dipropylphthalate

Time (min)	Flow Rate (mL/min)	%A	%B	Curve
Initial	1.0	95	5	–
2.70	1.0	5	95	6
3.00	1.0	5	95	6
3.12	1.0	95	5	6
4.00	1.0	95	5	6




## CONDITIONS


System:	ACQUITY UPLC® with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 μm, 2.1 x 100 mm (p/n 186007095)
Separation mode:	Isocratic (92:8 mobile phase A:B)
Mobile phase A:	20 mM potassium phosphate buffer pH 5.2
Mobile phase B:	85:15 mobile phase A/acetonitrile
Detection:	UV at 230 nm
Flow rate:	0.4 mL/min
Injection volume:	2.0 μL
Column temp.:	30 °C
Sample diluent:	Water
Standards:	Prepared to listed concentrations
Sample preparation:	Amoxicillin suspension diluted with water. Sample filtered through a 0.2 μm filter.




**Amoxicillin**



**6-Aminopenicillanic acid**




**Clavulanic acid**




### CONDITIONS


System:	ACQUITY UPLC® I-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 μm, 2.1 x 50 mm (p/n 186007093)
Mobile phase A:	0.1% formic acid in water
Mobile phase B:	0.1% formic acid in acetonitrile
Detection:	UV at 260 nm
Gradient:	See table
Flow rate:	0.6 mL/min
Injection volume:	1.0 μL
Column temp.:	30 °C
Sample diluent:	Water




Acetaminophen




2-Acetamidophenol



Acetylsalicylic acid




Caffeine




Acetanilide

Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.6	90	10
0.5	0.6	90	10
1.2	0.6	50	50
1.5	0.6	90	10
3.0	0.6	90	10




### CONDITIONS


System:	ACQUITY UPLC® I-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 μm, 2.1 x 50 mm (p/n 186007093) Competitor Solid-Core C <sub>18</sub> , 1.7 μm, 2.1 x 50 mm
Mobile phase A:	0.1% formic acid in water
Mobile phase B:	0.1% formic acid in acetonitrile
Detection:	UV at 254 nm
Flow rate:	0.6 mL/min
Gradient:	See table
Injection volume:	1.0 μL
Column temp.:	30 °C
Sample diluent:	20% acetonitrile in water




Carbadox



Sulfaquinoxaline




Oxolinic acid



Nalidixic acid

Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.6	95	5
4.0	0.6	50	50
4.1	0.6	95	5
5.0	0.6	95	5


### Antibacterials




Comparative separations may not be representative in all applications.

### CONDITIONS


System:	ACQUITY UPLC® with Xevo® G2 QToF Mass Spectrometer
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 μm, 2.1 x 100 mm (p/n 186007095)
Mobile phase A:	Water with 0.1% formic acid
Mobile phase B:	Acetonitrile with 0.1% formic acid
Flow rate:	0.6 mL/min
Gradient:	2 to 98% B in 5.5 minutes
Run time:	7 minutes
Injection volume:	1 μL
Column temp.:	30 °C
Scan mode:	ESI+ 200–1000 amu
Cone voltage:	30 V
Desolvation gas:	800 L/hr
Desolvation temp.:	280 °C
Capillary voltage:	3 kV
Sample:	375 mg <i>Astragalus</i> root extracted with 4 mL 50:50 EtoAc/methanol
Identification:	Mass extracted from total ion chromatogram (TIC) and compounds identified by accurate mass using MassLynx® Software




**Ononin**  
C<sub>22</sub>H<sub>22</sub>O<sub>9</sub>  
430.40




**Cycloastragenol**  
C<sub>30</sub>H<sub>50</sub>O<sub>5</sub>  
490.72



**Calycosin**  
C<sub>16</sub>H<sub>12</sub>O<sub>5</sub>  
284.26




**Formononetin**  
C<sub>16</sub>H<sub>12</sub>O<sub>4</sub>  
268.26



**CONDITIONS**


System: ACQUITY UPLC® with a Xevo® TQ-S Mass Spectrometer  
 Column: CORTECS® UPLC® C<sub>18</sub>, 1.6 μm, 2.1 mm x 50 mm  
 Mobile phase A: 0.1% formic acid in water  
 Mobile phase B: 0.1% formic acid in acetonitrile  
 Gradient: see Table  
 Column temp.: 35 °C  
 Sample temp.: 15 °C  
 Inj. volume: 10 μL  
 Total run time: 3.5 minutes  
 Collection plates: Waters 1 mL ACQUITY®  
 Collection Plates  
 Ionization mode: ESI positive  
 Capillary voltage: 3.0 kV  
 Desolvation temp.: 500 °C  
 Cone gas flow: 150 L/hr  
 Desolvation gas flow: 1000 L/hr



Bradykinin Amino Acid Sequence: RPPGFSPFR


Time (min)	Flow Rate (mL/min)	%A	%B	Curve
0.00	0.400	95.0	5.0	Initial
0.15	0.400	95.0	5.0	6
1.75	0.400	25.0	75.0	6
2.00	0.400	5.0	95.0	6
2.50	0.400	5.0	95.0	6
2.60	0.400	95.0	5.0	6
3.00	0.400	95.0	5.0	6

Endogenous levels of bradykinin extracted from human plasma




## CONDITIONS


System:	ACQUITY UPLC® I-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 µm, 2.1 x 50 mm (p/n 186007093)
Mobile phase A:	0.1% formic acid in water
Mobile phase B:	0.1% formic acid in acetonitrile
Detection:	UV at 280 nm
Gradient:	See table
Flow rate:	0.43 mL/min
Injection volume:	2.0 µL
Column temp.:	30 °C
Sample diluent:	Water




1-Methylxanthine




1,7-Dimethyluric acid



Caffeine




Theobromine



1,7-Dimethylxanthine


Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.6	95	5
2.2	0.6	76	24
2.5	0.6	95	5
4.0	0.6	95	5

Caffeine Metabolites




### CONDITIONS


System:	ACQUITY UPLC® H-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 μm, 2.1 x 100 mm (p/n 186007095)
Separation mode:	Isocratic
Mobile phase:	90:10 water/acetonitrile with 0.1% formic acid
Detection:	UV at 215 nm
Flow rate:	0.53 mL/min
Injection volume:	1.4 μL
Column temp.:	30 °C
Standards:	Prepared to 0.1 mg/mL in water
Sample:	0.2 g green tea extracted with 10 mL methanol and diluted using Milli-Q® water




Epigallocatechin




Epicatechin



Catechin




Gallo catechin gallate






## CONDITIONS


System:	ACQUITY UPLC® I-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 µm, 2.1 x 50 mm (p/n 186007093)
Mobile phase A:	0.1% formic acid in water
Mobile phase B:	0.1% formic acid in acetonitrile
Detection:	UV at 254 nm
Flow rate:	0.5 mL/min
Gradient:	See table
Injection volume:	1.4 µL
Column temp.:	30 °C
Sample diluent:	Water




Cefadroxil



Cefaclor




Cephalixin



Cephadrine

Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.5	95	5
2.0	0.5	80	20
2.1	0.5	95	5
3.0	0.5	95	5

## Cephalosporins




## Compounds:


1. Cefadroxil (20 µg/mL)
2. Cefaclor (20 µg/mL)
3. Cephalixin (20 µg/mL)
4. Cephadrine (50 µg/mL)

### CONDITIONS

System:	ACQUITY UPLC® with Xevo® G2 QToF Mass Spectrometer
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 μm, 2.1 x 50 mm (p/n 186007093)
Mobile phase A:	Water with 0.1% formic acid
Mobile phase B:	Acetonitrile with 0.1% formic acid
Flow rate:	0.6 mL/min
Gradient:	2 to 98% B in 5.5 minutes, hold 1 minute, equilibrate at 2% B
Run time:	7 minutes
Injection volume:	1 μL
Column temp.:	30 °C
Scan mode:	ESI+ 200–500 amu
Cone voltage:	30 V
Desolvation gas:	800 L/hr
Desolvation temp.:	280 °C
Capillary voltage:	3 kV
Sample:	600 mg <i>Cnidium Monnieri</i> extracted with 8 mL 50:50 EtoAc/methanol
Identification:	Mass extracted from total ion chromatogram (TIC) and compounds identified by accurate mass using MassLynx® Software




**Osthol**  
mw 244.28  
C<sub>15</sub>H<sub>16</sub>O<sub>3</sub>




### CONDITIONS


System:	ACQUITY UPLC® H-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 μm, 2.1 x 100 mm (p/n 186007095)
Mobile phase A:	0.1% trifluoroacetic acid in water
Mobile phase B:	Acetonitrile
Detection:	UV at 265 nm
Flow rate:	0.6 mL/min
Gradient:	See table
Injection volume:	1.0 μL
Column temp.:	30 °C
Standards:	Prepared to listed concentrations in water
Sample:	1 mL cough syrup diluted to 10 mL with water




Acetaminophen




Dextromethorphan



Chlorpheniramine




Diphenhydramine




Pseudoephedrine

Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.5	95	5
0.5	0.5	95	5
4.0	0.5	52	48
4.5	0.5	52	48
4.6	0.5	95	5
6.0	0.5	95	5




## CONDITIONS


System:	ACQUITY UPLC® with Xevo® G2 QToF Mass Spectrometer
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 μm, 2.1 x 100 mm (p/n 186007095)
Mobile phase A:	Water with 0.1% formic acid
Mobile phase B:	Acetonitrile with 0.1% formic acid
Flow rate:	0.6 mL/min
Gradient:	2 to 98% B in 5.5 minutes, hold 1 minute, equilibrate at 2% B
Run time:	7 minutes
Injection volume:	1 μL
Column temp.:	30 °C
Scan mode:	ESI+ 200–1500 amu
Cone voltage:	30 V
Desolvation gas:	800 L/hr
Desolvation temp.:	280 °C
Capillary voltage:	3 kV
Sample:	10 mL <i>Streptomyces</i> sp. fermentation broth extracted with 10 mL 80:20 EtoAc/methanol




**Erythromycin A**  
mw 733.93  
C<sub>37</sub>H<sub>67</sub>NO<sub>13</sub>



**Erythromycin A enol ether**  
mw 715.91  
C<sub>37</sub>H<sub>65</sub>NO<sub>12</sub>




**Erythromycin B**  
mw 717.93  
C<sub>37</sub>H<sub>67</sub>NO<sub>12</sub>




### CONDITIONS


System:	ACQUITY UPLC® H-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 μm, 2.1 x 100 mm (p/n 186007095)
Separation mode:	Isocratic
Mobile phase:	45:55 water/acetonitrile with 0.1% formic acid
Flow rate:	0.61 mL/min
Detection:	UV at 220 nm
Injection volume:	1.4 μL
Column temp.:	30 °C
Standards:	Prepared to 20 μg/mL in 50% acetonitrile in water
Sample:	1 birth control tablet dissolved into 1 mL of water, filtered through 0.2 μm filter




Estradiol




Ethinyl estradiol



Estrone




Levonorgestrel




## CONDITIONS


System:	ACQUITY UPLC® I-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 µm, 2.1 x 50 mm (p/n 186007093)
Mobile phase A:	0.1% trifluoroacetic acid in water
Mobile phase B:	Acetonitrile
Detection:	UV at 330 nm
Flow rate:	0.5 mL/min
Gradient:	See table
Injection volume:	1.0 µL
Column temp.:	30 °C
Sample diluent:	Water




Caftaric Acid



Echinacoside




Chlorogenic acid




Cichoric acid

Time (min)	%A	%B	Curve
Initial	92	8	–
0.10	92	8	6
4.45	50	50	7
4.86	10	90	6
5.00	92	8	6
6.00	92	8	6




Cynarin

## Phenolics in Echinacea




### CONDITIONS


System: ACQUITY UPLC® I-Class with ACQUITY® PDA  
 Column: CORTECS® UPLC® C<sub>18</sub>, 1.6 μm, 2.1 x 50 mm (p/n 186007093)  
 Mobile phase A: 0.1% formic acid in water  
 Mobile phase B: 0.1% formic acid in acetonitrile  
 Detection: UV at 248 nm  
 Gradient: See table  
 Flow rate: 0.6 mL/min  
 Injection volume: 2.0 μL  
 Column temp.: 30 °C  
 Sample diluent: 50:50 methanol/water



Pravastatin




Lovastatin



Simvastatin

Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.6	95	5
5.0	0.6	5	95
5.1	0.6	95	5
6.0	0.6	95	5





### CONDITIONS

System:	ACQUITY UPLC® I-Class with Xevo® TQD Mass Spectrometer
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 μm, 2.1 x 100 mm (p/n 186007095)
Column temp.:	30 °C
Injection volume:	5 μL
Flow rate:	0.6 mL/min.
Mobile phase A:	0.1% formic acid in Milli-Q® water
Mobile phase B:	0.1% formic acid in acetonitrile
Vials/plates:	96-well collection plates with 700 μL deactivated glass inserts (p/n 186000349DV)

Time (min)	%A	%B	Curve
Initial	70	30	–
2.0	50	50	6
3.0	50	50	6
7.0	10	90	6
7.2	70	30	6
8.5	70	30	6

To see the full application note, visit [www.waters.com](http://www.waters.com) and search for literature code: 720004780EN






## CONDITIONS

System:	ACQUITY UPLC® and ACQUITY® TQD Mass Spectrometer
Column:	CORTECS® UPLC® C <sub>18</sub> , 1.6 µm, 2.1 x 100 mm (p/n 186007095)
Column temp.:	30 °C
Injection volume:	10 µL
Flow rate:	0.6 mL/min
Mobile phase A:	0.1% formic acid in Milli-Q® water
Mobile phase B:	0.1% formic acid in acetonitrile
Vials/plates:	Ostro™ 96-well sample collection plates, 2.0 mL (p/n 186005518)

Time (min)	%A	%B	Curve
Initial	70	30	–
2.0	50	50	6
3.0	50	50	6
7.0	10	90	6
7.2	70	30	6
8.0	70	30	6

To see the full application note, visit [www.waters.com](http://www.waters.com)  
and search for literature code: 720004726EN

Calibration Standard at 20 ng/mL




- Compounds:
1. AM 2223
  2. RCS4, M10
  3. RCS-4, M11
  4. AM 1248
  5. JWH-073 4-butanoic acid met
  6. JWH-073 4-hydroxybutyl met
  7. JWH-018 5-pentanoic acid met
  8. JWH-073 (+/-) 3-hydroxybutyl met
  9. JWH-018 5-hydroxypentyl met
  10. JWH-018 (+/-) 4-hydroxypentyl met
  11. JWH-015
  12. RCS-4
  13. JWH-073
  14. JWH-022
  15. XLR-11
  16. JWH-203
  17. JWH-018
  18. RCS-8
  19. UR-144
  20. JWH-210
  21. AB 001
  22. AKB 48


## Analysis of Abacavir Related Compounds using CORTECS 2.7 µm Columns

### CONDITIONS


System: Alliance® HPLC with 2998 Photodiode Array Detector  
 Column: Fully-Porous C<sub>18</sub>, 5 µm, 4.6 x 150 mm  
 CORTECS® C<sub>18</sub>, 2.7 µm, 4.6 x 75 mm (p/n 186007376)  
 Mobile phase A: 0.1% trifluoroacetic acid in water  
 Mobile phase B: 85% methanol in water  
 Detection: UV at 254 nm  
 Gradient: See table  
 Column temp.: 30 °C  
 Sample: Abacavir USP Related Compounds  
 Sample diluent: Water




1. Descycleopropylabacavir




2. Abacavir



3. 1R,4R Trans abacavir



5. O-t-Butyl-abacavir





4. O-(4-Chloro-2,5-diaminopyrimidinyl)-abacavir

Gradient Time (min)					
4.6 x 150 mm	4.6 x 75 mm	2.1 x 50 mm	%A	%B	Curve
Initial	Initial	Initial	95	5	–
23.64	6.38	2.52	70	30	6
38.39	10.37	4.09	10	90	11
43.83	11.83	4.68	10	90	11
44.89	12.12	4.69	95	5	11

### Abacavir Related Compounds

Compounds:

1. Descycleopropylabacavir
2. Abacavir
3. 1R,4R Trans abacavir
4. O-(4-Chloro-2,5-diaminopyrimidinyl)-abacavir
5. O-t-Butyl-abacavir
- s. Solvent peak



### CONDITIONS

System: ACQUITY UPLC® H-Class System with ACQUITY® PDA Detector

Column: CORTECS® C<sub>18</sub>, 2.7 μm, 4.6 x 50 mm (p/n 186007375)

Fully Porous C<sub>18</sub>, 5 μm, 4.6 x 100 mm

Mobile phase A: 0.1% formic acid in water


Mobile phase B: 0.1% formic acid in acetonitrile

Detection: UV at 254 nm


Gradient: Linear from 5–50% B

Column temp.: 30 °C


Sample diluent: 20% acetonitrile in water




Carbadox



Oxolinic acid




Sulfaquinoxaline



Nalidixic acid

### Antibacterials



### CONDITIONS

System: ACQUITY UPLC® with TQD Mass Spectrometer

Column: CORTECS® C<sub>18</sub>, 2.7 µm, 4.6 x 100 mm (p/n 186007377)

Mobile phase A: 0.1% formic acid in water

Mobile phase B: 0.1% formic acid in acetonitrile

Flow rate: 2.0 mL/min

Gradient: See table

Injection volume: 9.6 µL

Column temp.: 40 °C

Sample: LCMS QCRM (p/n 186006963)

Capillary voltage: 3.8 kV

Cone voltage: 30 V

Extractor: 3 V

RF lens: 0.0 V


Ion energy: 0.5

Source temp: 120 °C


Desolvation temp: 450 °C

Desolvation flow: 1000 L/hr


Cone flow: 30 L/hr




Sulfaguanidine




Acetaminophen




L-leucine




Sulfadimethoxine




Terfenadine



Val-Tyr-Val




Verapamil



Reserpine

Time (min)	Flow Rate (mL/min)	%A	%B	Curve
0.00	2.0	95	5	–
9.60	2.0	25	75	6
10.0	2.0	25	75	6
10.1	2.0	75	25	6
12.0	2.0	75	25	6




### CONDITIONS

System:	ACQUITY UPLC® H-Class with Xevo® TQD Mass Spectrometer	Capillary voltage:	1.5 kV
Column:	CORTECS® C <sub>18</sub> , 2.7 μm, 2.1 x 100 mm (p/n 186007367)	Desolvation temp.:	500 °C
Mobile phase A:	Water + 0.1% formic acid	Desolvation gas flow:	1000 L/Hr
Mobile phase B:	Methanol + 0.1% formic acid	Source temp.:	150 °C
Mobile phase C:	Acetonitrile + 0.1% formic acid		
Flow rate:	0.4 mL/min		
Gradient:	See table		
Injection volume:	5 μL		
Column temp.:	45 °C		
Sample:	Sudan Dyes in Oleoresin		
Sample preparation	Oleoresin prepared using Certified Sep-Pak® Silica 3 cc Vac Cartridge, 500 mg sorbent per cartridge, 55–105 μm particle Size (p/n 186004615)		
Ionization mode:	ESI+		

Time (min)	Flow Rate (mL/min)	%A	%B	%C	Curve
Initial	0.4	80	10	10	–
0.5	0.4	40	30	30	6
5.0	0.4	0	50	50	6
9.0	0.4	0	50	50	6
9.1	0.4	80	10	10	6
12.0	0.4	80	10	10	6

100ppb Spiked Sudan Dyes in Oleoresin



### CONDITIONS

System: ACQUITY UPLC® I-Class System (SM-FL),  
Column Manager (CMA) with  
Xevo® TQD Mass Spectrometer

Column: CORTECS® C<sub>18</sub>, 2.7 μm,  
2.1 x 100 mm (p/n 186007367)

Mobile phase A: 0.1% formic acid in water

Mobile phase B: 0.1% formic acid in acetonitrile


Gradient: See table

Injection volume: 5 μL

Column temp.: 30 °C

Sample: Synthetic Cannabinoid Mix


Challenge Sample: Prepared plasma using  
Ostro™ Sample Preparation  
Plate (p/n 186005518)



Time (min)	%A	%B	Curve
Initial	70	30	–
3.0	50	50	6
4.5	50	50	6
10.5	10	90	6
13.0	10	90	6
13.1	70	30	11
15.0	70	30	11

### Synthetic Cannabinoids

Peak	Compound	Retention Time	
		Initial Injection	Injection 1000
2	RCS-4, M10	1.91	1.90
10	JWH-018, 4-OH met.	4.18	4.18
21	AB 001	10.49	10.48
Pressure		3753	3749



## Quantification of Acetylcholine, Histamine, and their Metabolites in Human Cerebrospinal Fluid (CSF) using CORTECS UPLC 1.6 µm Columns

### CONDITIONS

System: ACQUITY UPLC® with Xevo® TQ-S Mass Spectrometer

Column: CORTECS® UPLC® HILIC, 1.6 µm,  
2.1 x 100 mm (p/n 186007106)

Mobile phase A: 100 mM ammonium formate, pH 3

Mobile phase B: Acetonitrile


Flow rate: 0.5 mL/min

Column temp.: 45 °C


Sample temp.: 6 °C

Injection volume: 10 µL


Collection plates: Waters® ACQUITY®  
1-mL collection plates




Acetylcholine (ACh)




Choline (Ch)



Histamine (HA)




tele-Methylhistamine (t-mHA)



tele-Methylimidazoleacetic acid (t-MIAA)


Time (min)	Flow Rate (mL/min)	%A	%B	Curve
Initial	10	90	–	–
0.75	40	60	6	6
1.00	40	60	6	6
1.25	70	30	6	6
1.90	10	90	11	6

To see the full application note, visit [www.waters.com](http://www.waters.com)  
and search for literature code: 720004722EN




### CONDITIONS


System:	ACQUITY UPLC® with ACQUITY® PDA
Column:	CORTECS® UPLC® HILIC, 1.6 µm, 2.1 x 100 mm (p/n 186007106)
Separation mode:	Isocratic (15:85 mobile phase A:B)
Mobile phase A:	0.2% formic acid in water
Mobile phase B:	0.2% formic acid in acetonitrile
Detection:	UV at 254 nm
Flow rate:	0.6 mL/min
Injection volume:	0.4 µL
Column temp.:	30 °C
Sample diluent:	0.02 N sodium hydroxide in 60:40 acetonitrile/water



**Acyclovir**



**Guanine**







## CONDITIONS

System: ACQUITY UPLC® H-Class with ACQUITY® PDA  
 Column: CORTECS® UPLC® HILIC, 1.6 µm, 2.1 x 100 mm (p/n 186007106)  
 Mobile phase A: 50:50 acetonitrile/10 mM ammonium formate with 0.125% formic acid  
 Mobile phase B: 90:10 acetonitrile/10 mM ammonium formate with 0.125% formic acid  
 Detection: UV at 265 nm  
 Flow rate: 0.6 mL/min  
 Gradient: See table  
 Injection volume: 1.0 µL  
 Column temp.: 30 °C  
 Sample diluent: 75:25 acetonitrile/methanol with 0.2% formic acid


Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.6	0.1	99.9
1.0	0.6	0.1	99.9
2.6	0.6	99.9	0.1
2.7	0.6	0.1	99.9
3.5	0.6	0.1	99.9




Acetaminophen




Dextromethorphan




Chlorpheniramine



Diphenhydramine




Pseudoephedrine




### CONDITIONS


System:	ACQUITY UPLC® H-Class with Xevo® TQD Mass Spectrometer
Column:	CORTECS® UPLC® HILIC, 1.6 µm, 2.1 x 50 mm (p/n 186007104)
Mobile phase A:	50:50 acetonitrile/10 mM ammonium formate with 0.125% formic acid
Mobile phase B:	95:5 acetonitrile/10 mM ammonium formate with 0.125% formic acid
Detection:	ESI+, scan m/z 100–300
Flow rate:	0.5 mL/min
Gradient:	See table
Capillary voltage:	1 kV
Cone voltage:	30 V
Desolvation gas:	800 L/hr
Desolvation temp.:	300 °C
Injection volume:	5.0 µL
Sample diluent:	75:25 acetonitrile/methanol with 0.2% formic acid



**Creatine**




**Carnosine**




**Anserine**

Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.5	0.1	99.9
5	0.5	99.9	0.1
5.01	0.5	0.1	99.9
6	0.5	0.1	99.9




### CONDITIONS


System:	ACQUITY UPLC® I-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® HILIC, 1.6 µm, 2.1 x 50 mm (p/n 186007104)
Mobile phase A:	50:50 acetonitrile/10 mM ammonium formate with 0.125% formic acid
Mobile phase B:	90:10 acetonitrile/10 mM ammonium formate with 0.125% formic acid
Detection:	UV at 245 nm
Gradient:	See table
Flow rate:	0.8 mL/min
Injection volume:	5.0 µL
Column temp.:	30 °C
Sample diluent:	75:25 acetonitrile/methanol with 0.2% formic acid




Lidocaine




Butacaine



Tetracaine




Procaine




Procainamide

Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.8	0.1	99.9
1.0	0.8	0.1	99.9
2.6	0.8	99.9	0.1
2.7	0.8	0.1	99.9
3.5	0.8	0.1	99.9




### CONDITIONS


System:	ACQUITY UPLC® I-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® HILIC, 1.6 μm, 2.1 x 50 mm (p/n 186007104)
Mobile phase A:	50:50 acetonitrile/10 mM ammonium formate with 0.125% formic acid
Mobile phase B:	90:10 acetonitrile/10 mM ammonium formate with 0.125% formic acid
Detection:	UV at 280 nm
Flow rate:	1.235 mL/min
Gradient:	See table
Injection volume:	5 μL
Column temp.:	30 °C
Sample diluent:	Mobile phase B




**6-Acetylmorphine**



**Morphine-N-oxide**




**Morphine**



**Morphine-3β-glucuronide**


Time (min)	Flow Rate (mL/min)	%A	%B
0.00	1.235	0.1	99.9
0.51	1.235	0.1	99.9
2.11	1.235	99.9	0.1
2.19	1.235	0.1	99.9
3.00	1.235	0.1	99.9

### Morphine Metabolites




### CONDITIONS


System:	ACQUITY UPLC® I-Class with ACQUITY® PDA
Column:	CORTECS® UPLC® HILIC, 1.6 µm, 2.1 x 50 mm (p/n 186007104)
Mobile phase A:	50:40:10 acetonitrile/methanol/20 mM ammonium acetate with 0.05% acetic acid
Mobile phase B:	90:5:5 acetonitrile/methanol/4 mM ammonium acetate with 0.01% acetic acid
Detection:	UV at 254 nm
Flow rate:	0.45 mL/min
Gradient:	See table
Injection volume:	0.4 µL
Column temp.:	30 °C
Sample diluent:	75:25 acetonitrile/methanol with 0.2% formic acid




Thiourea




Thymine



Cytosine




Thymidine





5-Fluorocytosine

Time (min)	Flow Rate (mL/min)	%A	%B
0.00	0.45	0.1	99.9
0.51	0.45	0.1	99.9
2.11	0.45	99.9	0.1
2.19	0.45	0.1	99.9
3.00	0.45	0.1	99.9



## CONDITIONS

System:	ACQUITY UPLC® H-Class with photodiode array (PDA) detection with ACQUITY® TQD Mass Spectrometer
Column:	CORTECS® UPLC® HILIC, 1.6 µm, 2.1 x 100 mm (p/n 186007106)
Separation mode:	Isocratic (50:50 mobile phase A:B)
Mobile phase A:	200 mM ammonium formate buffer at pH 3.7
Mobile phase B:	Acetonitrile
Injection volume:	20 µL
Column temp.:	30 °C
Flow rate:	0.5 mL/min
PDA detection:	Diquat UV at 308 nm, paraquat UV at 257 nm
Sample vials:	Polypropylene autosampler vials (p/n 186002642)




## MRM Transitions

Compound	MRM	Cone (V)	CID (eV)
Diquat	183.1 > 157.1	50	25
	183.1 > 130.1	50	30
Paraquat	185.1 > 170.1	38	22
	171.1 > 77.0	45	40


To see the full application note, visit [www.waters.com](http://www.waters.com) and search for literature code: 720004732EN

Paraquat and Diquat in Drinking Water




**CONDITIONS**

System: ACQUITY UPLC® H-Class with ACQUITY® TQD Mass Spectrometer  
 Column: CORTECS® HILIC, 1.6 µm, 2.1 x 100 mm (p/n 186007106)  
 Isocratic: 50:50 A/B  
 Mobile phase A: 200 mM ammonium formate buffer at pH 3.7  
 Mobile phase B: Acetonitrile  
 Injection volume: 20 µL  
 Column temp.: 30 °C  
 Wash solvent: 50:50 acetonitrile/water  
 Purge solvent: 50:50 acetonitrile/water  
 Flow rate: 0.5 mL/min  
 Sample vials: Polypropylene autosampler vials (p/n 186002642)  
 Ionization mode: Positive Electropray  
 Source temp.: 150 °C  
 Desolvation temp.: 350 °C  
 Desolvation gas flow: 800 L/hr  
 Cone gas flow: 30 L/hr  
 Collision gas flow: 0.20 mL/min



Paraquat




Diquat

**MRM Transitions**




Compound	MRM	Cone (V)	CID (eV)
Diquat	183.1 > 157.1	50	25
	183.1 > 130.1	50	30
Paraquat	185.1 > 170.1	38	22
	171.1 > 77.0	45	40

Paraquat and diquat in potato




### CONDITIONS

System:	ACQUITY UPLC® with ACQUITY® PDA
Column:	CORTECS® UPLC® HILIC, 1.6 µm, 2.1 x 50 mm (p/n 186007104)
Mobile phase A:	50:50 acetonitrile/10 mM ammonium formate with 0.125% formic acid
Mobile phase B:	90:10 acetonitrile/10 mM ammonium formate with 0.125% formic acid
Detection:	UV at 265 nm
Flow rate:	0.5 mL/min
Gradient:	See table
Injection volume:	5.0 µL
Column temp.:	30 °C
Sample diluent:	75:25 acetonitrile/methanol with 0.2% formic acid



Time (min)	Flow Rate (mL/min)	%A	%B
Initial	0.5	0.1	99.9
5.0	0.5	99.9	0.1
5.1	0.5	0.1	99.9
6.0	0.5	0.1	99.9







### CONDITIONS

System:	ACQUITY UPLC® H-Class with Xevo® TQD Mass Spectrometer
Column:	CORTECS® HILIC, 2.7 µm, 2.1 x 100 mm (p/n 186007382)
Flow rate:	0.28 mL/min
Mobile phase A:	Water + 0.1% acetic acid/ammonium acetate buffer (1 g/L water)
Mobile phase B:	Acetonitrile
Gradient:	See table
Column temp.:	45 °C
Sample:	Basic drugs from river water
Sample preparation	200 mL river water (pH 5.0 with acetic acid) prepared using Oasis® MCX 6 cc Vac Cartridge, 150 mg sorbent per cartridge, 30 µm particle size) (p/n 186000256)
Ionization mode:	ESI+
Capillary voltage:	1.5 kV
Desolvation temp.:	500 °C
Desolvation gas flow:	1000 L/Hr
Source temp.:	150 °C


Time (min)	Flow Rate (mL/min)	%A	%B	Curve
Initial	0.280	2	98	–
4.50	0.280	30	70	6
10.80	0.280	30	70	6
11.25	0.280	2	98	6
14.40	0.280	2	98	6
4.50	0.280	2	98	6




Metformin




Salbutamol



Cimetidine








Clenbuterol



Ranitidine

### 25 ppt Spiked River Water




## CONDITIONS


System: ACQUITY UPLC® with PDA Detector  
Column: CORTECS® HILIC, 2.7 µm,  
4.6 x 100 mm (p/n 186007392)  
Mobile phase: 90:10 acetonitrile/100 mM ammonium  
formate (pH 3.0) (v/v)  
Flow rate: 2.0 mL/min  
Separation: Isocratic  
Injection volume: 9.6 µL  
Column temp.: 30 °C  
Sample: HILIC QCRM (p/n 186007226)




**Acenaphthene**




**Thymine**



**Adenine**




**Cytosine**




### CONDITIONS


System:	Alliance® HPLC with 2998 Photodiode Array Detector
Column:	CORTECS® HILIC, 2.7 µm, 4.6 x 150 mm (p/n 186007393)
Mobile phase A:	10 mM ammonium formate in 50% acetonitrile/49.875% water/0.125% formic acid
Mobile Phase B:	10 mM ammonium formate in 90% acetonitrile/9.875% water/0.125% formic acid
Detection:	UV at 280 nm
Flow rate:	1.99 mL/min
Gradient:	See table
Injection volume:	14.4 µL
Column temp.:	30 °C
Sample:	Morphine Metabolites
Sample diluent:	Mobile phase B




**6-Acetylmorphine**



**Morphine-N-oxide**




**Morphine**



**Morphine-3β-glucuronide**

Time (min)	%A	%B	Curve
Initial	0.1	99.9	–
4.42	0.1	99.9	6
18.29	99.9	0.1	6
18.99	0.1	99.9	11
26.01	0.1	99.9	11

*Morphine Metabolites*



Compounds:

1. 6-Acetylmorphine (0.2 mg/mL)
2. Morphine (0.2 mg/mL)
3. Morphine-N-oxide (0.1 mg/mL)
4. Morphine-3β-glucuronide (0.2 mg/mL)

**SALES OFFICES:**

Austria 43 1 877 18 07  
Australia 61 2 9933 1777  
Belgium and Luxembourg 32 2 726 1000  
Brazil 55 11 4134 3788  
Canada 1 800 252 4752  
China 86 21 6156 2666  
Czech Republic 420 2 617 11384  
Denmark 45 46 59 8080  
Finland 358 9 5659 6288  
France 33 1 30 48 72 00  
Germany 49 6196 400 600  
Hong Kong 852 2964 1800  
Hungary 36 1 350 5086  
India 91 080 49292200 03  
Ireland 353 1 448 1500  
Israel 9723 3731391  
Italy 39 02 265 0983  
Japan 81 3 3471 7191  
Korea 82 2 6300 9200  
Mexico 52 55 52 00 1860  
The Netherlands 31 76 508 7200  
Norway 47 6 384 6050  
Poland 48 22 101 5900  
Portugal 351 21 893 61 77  
Puerto Rico 1 787 747 8445  
Russia/CIS 7 495 727 4490 / 290 9737  
Singapore 65 6593 7100  
Spain 34 93 600 9300  
Sweden 46 8 555 115 00  
Switzerland 41 56 676 7000  
Taiwan 886 2 2501 9928  
UK 44 208 238 6100  
US 1 800 252 4752

[www.waters.com/CORTECS](http://www.waters.com/CORTECS)

# Waters

THE SCIENCE OF WHAT'S POSSIBLE.®

**Waters Corporation**

34 Maple Street  
Milford, MA 01757 U.S.A.  
T: 508 478 2000  
F: 508 872 1990  
[www.waters.com](http://www.waters.com)

Waters, The Science of What's Possible, CORTECS, ACQUITY UPLC, ACQUITY, UPLC, Xevo, and MassLynx are registered trademarks of Waters Corporation. Ostro is a trademark of Waters Corporation. All other trademarks are the property of their respective owners.

©2014 Waters Corporation. Produced in the U.S.A.  
May 2014 720004739EN IH-PDF